نتایج جستجو برای: lenalidomide
تعداد نتایج: 3060 فیلتر نتایج به سال:
F irst, the most important and biggest subgroup of CLL patients—the elderly, who are usually neglected in clinical trials—is studied. Second, the authors were ambitious enough to design a nonchemotherapeutic first-line treatment approach for these patients. Third, they included carefully preplanned correlative analysis not only focusing on the usual biologic disease characteristics but also on ...
Ferrajoli and colleagues present the results of a phase 2 study in which lenalidomide was administered by continuous daily dosing to 44 patients with relapsed CLL. Clinical activity (ORR 32%, CR 7%) was observed, and responses were seen in patients with poor-risk cytogenetic abnormalities and unmutated IgVH. However, the mechanism(s) of action and the optimal dosing schedule of lenalidomide rem...
BACKGROUND This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma. METHODS We randomly assigned 273 patients 65 years o...
The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM). Preclinical data showed that the Akt inhibitor, perifosine, sensitized MM cells to lenalidomide and dexamethasone, providing the rationale for this Phase I, multicentre, single-arm study to assess the safety and determine the maximum-tolerated dose (MTD) of perifosine-lenalidomide-dexamethasone in relapsed and rel...
BACKGROUND Multiple myeloma (MM) is a cancer caused by malignant plasma cells that accumulate mostly in the bone marrow. In Canada, the most common maintenance therapy options after autologous stem cell transplant (ASCT) are bortezomib and lenalidomide. OBJECTIVE To determine the incremental cost between bortezomib and lenalidomide maintenance therapies for patients with MM post ASCT. METHO...
Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006. In April 2005, the FDA and patient advocacy groups requested an expanded access programme to both provide lenalidomide to patients likely to benefit and obtain additional safety information. Relapsed/refractor...
Lenalidomide belongs to a group of immunomodulatory drugs (IMiDs), fi rst known with the discovery of thalidomide in the 1950s, and which have then be tested in various malignancies for their clinical potential. It is described that these IMiDs exhibit multiple biologic effects on cytokine and cell-mediated responses. Lenalidomide was developed by chemical modifi cation of thalidomide to enhanc...
The aim of this study was to evaluate the efficacy and adverse effects of lenalidomide in the treatment of intermediate-1 risk non-5q deletion [non-del (5q)] myelodysplastic syndrome (MDS). A total of 30 patients with MDS were classified through G-banding chromosome karyotype analysis and fluorescence in situ hybridization (FISH). According to the International Prognostic Scoring System scores,...
The immunomodulatory drug lenalidomide is highly effective against newly diagnosed and relapsed/refractory multiple myeloma (MM), but serious and even fatal infections have been associated with its use. In this meta-analysis, we assessed the overall risk of infection to MM patients treated with lenalidomide. Eleven phase II or III clinical trials, comprising 3,210 subjects, were selected from t...
Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting. We evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed and refractory MM. Patients (N = 222) received lenalidomide 30 mg/day once daily (days 1-21 every 28 days) until disease progression...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید